Volume 10, Issue 12, Pages 1145-1151 (December 2009) Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial  Prof Heikki Joensuu, MD, Prof Pirkko-Liisa Kellokumpu-Lehtinen, MD, Riikka Huovinen, MD, Arja Jukkola-Vuorinen, MD, Minna Tanner, MD, Raija Asola, MD, Riitta Kokko, MD, Johan Ahlgren, MD, Päivi Auvinen, MD, Prof Akseli Hemminki, MD, Outi Paija, MD, Leena Helle, MD, Lauri Nuortio, MD, Kenneth Villman, MD, Greger Nilsson, MD, Sirpa-Liisa Lahtela, MD, Kaisa Lehtiö, MD, Marjo Pajunen, MD, Paula Poikonen, MD, Paul Nyandoto, MD, Vesa Kataja, MD, Petri Bono, MD, Mika Leinonen, MSc, Henrik Lindman, MD  The Lancet Oncology  Volume 10, Issue 12, Pages 1145-1151 (December 2009) DOI: 10.1016/S1470-2045(09)70307-9 Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2009 10, 1145-1151DOI: (10.1016/S1470-2045(09)70307-9) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier estimates of 3-year recurrence-free and overall survival in the modified intention-to-treat population The Lancet Oncology 2009 10, 1145-1151DOI: (10.1016/S1470-2045(09)70307-9) Copyright © 2009 Elsevier Ltd Terms and Conditions

Figure 3 Forest plot of exploratory subgroup analyses for recurrence-free survival The Lancet Oncology 2009 10, 1145-1151DOI: (10.1016/S1470-2045(09)70307-9) Copyright © 2009 Elsevier Ltd Terms and Conditions